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Abstract
Introduction: HIV care and treatment programmes worldwide are transforming as they push to deliver universal access to
essential prevention, care and treatment services to persons living with HIV and their communities. The characteristics and
capacity of these HIV programmes affect patient outcomes and quality of care. Despite the importance of ensuring optimal
outcomes, few studies have addressed the capacity of HIV programmes to deliver comprehensive care. We sought to describe
such capacity in HIV programmes in seven regions worldwide.
Methods: Staff from 128 sites in 41 countries participating in the International epidemiologic Databases to Evaluate AIDS completed
a site survey from 2009 to 2010, including sites in the Asia-Pacific region (n20), Latin America and the Caribbean (n7),
North America (n7), Central Africa (n12), East Africa (n51), Southern Africa (n16) and West Africa (n15). We com-
puted a measure of the comprehensiveness of care based on seven World Health Organization-recommended essential HIV services.
Results: Most sites reported serving urban (61%; region range (rr): 33100%) and both adult and paediatric populations (77%;
rr: 2996%). Only 45% of HIV clinics that reported treating children had paediatricians on staff. As for the seven essential
services, survey respondents reported that CD4 cell count testing was available to all but one site, while tuberculosis (TB)
screening and community outreach services were available in 80 and 72%, respectively. The remaining four essential services 
nutritional support (82%), combination antiretroviral therapy adherence support (88%), prevention of mother-to-child
transmission (PMTCT) (94%) and other prevention and clinical management services (97%)  were uniformly available.
Approximately half (46%) of sites reported offering all seven services. Newer sites and sites in settings with low rankings on the
UN Human Development Index (HDI), especially those in the President’s Emergency Plan for AIDS Relief focus countries, tended
to offer a more comprehensive array of essential services. HIV care programme characteristics and comprehensiveness varied
according to the number of years the site had been in operation and the HDI of the site setting, with more recently established
clinics in low-HDI settings reporting a more comprehensive array of available services. Survey respondents frequently identified
contact tracing of patients, patient outreach, nutritional counselling, onsite viral load testing, universal TB screening and the
provision of isoniazid preventive therapy as unavailable services.
Conclusions: This study serves as a baseline for on-going monitoring of the evolution of care delivery over time and lays the
groundwork for evaluating HIV treatment outcomes in relation to site capacity for comprehensive care.
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Introduction
By the end of 2012, an estimated 35 million people world-
wide were living with HIV, of whom 71% resided in sub-
Saharan Africa [1]. International donors and individual
countries are striving to scale up combination antiretroviral
therapy (ART) to reach the 28.3 million people eligible for
treatment in 2013 [1]. HIV care and treatment programmes,
particularly in resource-limited settings where the vast
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majority of eligible adults reside, are expanding to support
the implementation of HIV prevention, care and treatment
interventions. However, programme coverage remains insuf-
ficient and is not evenly distributed [2]. Monitoring key pro-
gramme outcomes (e.g. immunologic, virologic and clinical
response to treatment; survival; adherence to treatment; and
retention in care) and programme targets (e.g. number of
patients enrolled in care and initiating ART) has provided
insights into the successes and challenges of HIV treatment
scale-up [312], just as intensive reviewing of data from
national HIV response plans and monitoring and evaluation
systems has revealed the challenges of programme imple-
mentation in resource-limited settings [13,14].
Observational studies relate site and programme charac-
teristics to improved patient and programme outcomes [13,15],
including higher CD4 cell count at the time of ART initia-
tion [16,17] and improved ART medication adherence [18],
service utilization [19] and loss to follow-up in HIV care [20].
Such analyses are an important part of the larger agenda of
rigorous evaluation and implementation science in any large-
scale service or prevention programme [13,21,22]. Under-
standing programme characteristics, their evolution over
time and how these characteristics may influence patient
outcomes such as retention in care, immunodeficiency at ART
initiation and response to ART strengthens the process of
constructing and implementing more effective HIV care and
treatment programmes.
The comprehensiveness of HIV care services may also play
an important role in influencing patient and programme
outcomes, but it has not been well described. Comprehen-
sive HIV care depends on the provision of diverse services, in-
cluding HIV prevention services, HIV counselling and testing,
prevention of illness, management of opportunistic infections
and comorbidities, ART adherence support, patient monitor-
ing on ART and palliative care [2325]. The World Health
Organization (WHO) has identified these recommended ser-
vices as HIV priority interventions [2].
In this analysis, we outlined the facility and programme
characteristics in a large global network of HIV clinical sites
and assessed the ‘‘comprehensiveness’’ of HIV prevention,
care and treatment service availability. We compared the
comprehensive care capacity of established, resource-rich
sites to that of newer sites in resource-limiting settings.
Methods
The International epidemiologic Databases to Evaluate AIDS
(IeDEA) consortium (http://www.iedea.org) is a research net-
work of HIV care and treatment programmes in seven geo-
graphical regions: Asia-Pacific, the Caribbean/Latin America,
North America, Central Africa, East Africa, Southern Africa
and West Africa [2630]. Each IeDEA region has an inde-
pendent data centre and governance structure, although the
regions collaborate on cross-region projects. IeDEA is funded
by the US National Institutes of Health (NIH) to address
key clinical and operational research questions that require
data on large numbers of patients receiving care across a
spectrum of clinical care settings.
Survey development
IeDEA investigators developed a 164-item site survey to elicit
information on site characteristics including the following:
. the facility housing the HIV clinic (facility level, teaching
affiliation and public or private sector);
. the HIV care clinic (number of clinic days per week that
the clinic provides HIV services, year ART services began
and current waiting list for ART);
. the patient population (adult/paediatric and urban/
rural patients);
. components of the HIV care programme (voluntary
counselling and testing, HIV prevention services, pre-
vention of mother-to-child transmission (PMTCT) of HIV
and nutritional services);
. available support services (availability of ART adherence
services, outreach to patients who miss appointments
and a peer educator programme);
. available laboratory services (CD4 cell count: onsite,
offsite or not available; CD4 cell count turnaround
time; HIV-1 viral load: onsite, offsite or not available;
and labs to monitor adverse events);
. prevention, diagnosis and management of co-infections
(tuberculosis (TB) and malaria) and malignancies;
. supply chain reliability (frequency of ART medication
and CD4 cell count reagent stock-outs);
. the ART pharmacy; and
. the cadres of HIV clinic staff.
English and French versions of the IeDEA site survey were
available either online or as paper-based instruments. The
online version was implemented using REDCap, a secure,
web-based application designed and hosted at Vanderbilt
University to support data capture for research studies [31].
The paper-based survey was translated from English into
French, Spanish and Portuguese by professional translators at
the NIH Clinical Center in Bethesda, United States.
Data collection
All seven IeDEA regions agreed to participate in the study.
Data managers from each IeDEA region distributed a link to
the web-based site assessment survey and a PDF of the
paper survey to clinical staff at the adult-only or combined
adult-paediatric care clinics within their geographic region.
Any surveys returned on paper were entered into REDCap
and verified by the regional data teams. The Southern Africa
region completed a subset of the survey questions, soliciting
data on facility characteristics and opportunistic infection
management, but not on other programme characteristics or
laboratory capacity. Southern Africa used the WHO DataCol
software package (https://extranet.who.int/datacol/home.asp),
which was an established data collection tool in their region,
and entered data in duplicate into REDCap.
The site assessment was conducted in all seven IeDEA
regions from August 2009 to February 2010. The sites and
coordinating centres for all IeDEA regions had Institutional
Review Board approvals in place that permitted the collec-
tion of such operational data through this site assessment
survey. The protocol was reviewed by Columbia University
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Institutional Review Board and received nonhuman subject
research determination, as the subjects of data collection
were facilities and not individuals.
Comprehensiveness assessment
Authors, including HIV clinicians, identified questions on the
already-finalized survey that addressed essential HIV compre-
hensive care services as described by WHO and published
literature [2,23,24]. We assembled these questions into a
comprehensiveness metric based on the site-level availability of
seven essential services: (1) ART adherence support, defined as
providing on a routine basis one-on-one adherence counselling,
reminders and review ofmedication pickup; (2) CD4 cell count
testing onsite or offsite; (3) HIV prevention services: specifically
the availability of HIV testing and counselling, the provision of
co-trimoxazole (TMP-SMX) for Pneumocystis jiroveci (formerly
carinii) pneumonia (PCP) prophylaxis and at least two other
prevention services (education on high-risk behaviours, screen-
ing for substance abuse and sexually transmitted infections,
family planning, post-exposure prophylaxis and/or adult male
circumcision); (4) PMTCT services, either onsite or offsite and
linkedwith onsite care; (5) nutritional counselling and support,
including provision of multivitamins, mineral supplements and
nutritional ‘‘treatment’’ for malnutrition, or an onsite nutri-
tionist; (6) universal screening for TB symptoms; and (7) com-
munity outreach and contact tracing for ART-treated adults
with missed clinic appointments. These services were included
in the Priority Interventions recommended by WHO [2].
We evaluated the availability of these seven essential HIV
comprehensive care services for every clinic that completed all
the associated survey questions.
Sites were grouped into comprehensiveness categories of
low (35 essential services), medium (6 essential services) or
high (all 7 essential services). We evaluated the availability
of essential services according to site characteristics, such as
urban or rural patient population, year of first ART availability
for adults, country rank on the 2010 UN Human Development
Index (HDI) (rankings that take into account per capita
income as well as life expectancy) [32] and US President’s
Emergency Plan for AIDS Relief (PEPFAR) focus country status
as of 2008 [33].
Statistical considerations
Data from each of the seven regions were merged, cleaned
and analysed using Microsoft Excel and the R statistical
software package. Analyses included descriptive statistics and
frequency calculations. Analysis scripts are available on the
Vanderbilt University Department of Biostatistics wiki (http://
biostat.mc.vanderbilt.edu/ArchivedAnalyses). Descriptive sta-
tistics of programme and facility characteristics are presented
by region and by comprehensiveness category.
Results
One hundred and thirty-three HIV care and treatment sites
within IeDEA were approached for participation in this study,
and 128 of 133 (96%) completed the site survey. The number
of participating sites per region varied from seven each in
Caribbean/Latin America and North America to 51 in East
Africa. Figure 1 depicts the geographic distribution of the
sites, and site characteristics are outlined in Table 1.
Most of the 128 clinics reported serving urban populations
(61%). This pattern was consistent across regions with the
exception of East Africa (33%). All clinics provided HIV care to
adult patients and the majority of clinics (77%) also provided
care to children; across regions, this ranged from 29% in
North America to 96% in East Africa. Most HIV clinics defined
themselves as being located within primary care facilities
(38%; region range (rr): 558%) or tertiary care facilities
(41%; rr: 1490%). Only East Africa had a substantial pro-
portion of HIV clinics in secondary-level health facilities (37%).
Most facilities were publicly funded (79%), except in Central
Africa (44%). Most clinics in North America, Caribbean/Latin
America and Asia-Pacific began offering HIV treatment
before 2000, whereas the clinics in the less resourced regions
of sub-Saharan Africa began offering ART more recently
(Table 1).
Staff capacity varied by IeDEA region: 83% of HIV clinics
reported having onsite physicians, ranging from 61% in East
Africa to 100% in North America, Caribbean/Latin America,
Asia-Pacific and Central Africa. However, paediatricians were
only available at 37% of all HIV clinics (from 17% in Central
Africa to 57% in Caribbean/Latin America) and at 45% of HIV
clinics that reported treating children. Sites reported that
mid-level providers (clinical officers, nurse practitioners and
physician assistants) were available at 56% of HIV clinics
across all regions, ranging from 20% in West Africa to 86% in
North America and East Africa.
Programme characteristics and clinical services
Table 2 lists characteristics of the HIV care and treatment pro-
grammes in six IeDEA regions, as self-reported by participat-
ing sites. Two HIV prevention services were almost universally
available: HIV counselling and testing (97%; rr: 86100%) and
HIV disclosure counselling (94%; rr: 83100%). Condoms
were less commonly provided by HIV clinics in West Africa
(47%) than in other regions (range: 70100%), while only
North America routinely provided drug and alcohol abuse
screening (100%, vs. 1460%) and substance use and harm
reduction education (100%, vs. 3365%). Adult male circum-
cision was offered at 38% of all clinics. East Africa was an
exception with 65% of sites offering adult male circumcision.
co-trimoxazole (or the equivalent, including SeptraTM or
Bactrim) prophylaxis was available at 97% of sites (rr: 92
100%). One hundred and seven sites (95%) reported available
patient support services, especially patient support groups
and peer educator programmes, available at 88% (rr: 86
100%) and 67% (rr: 5075%) of clinics, respectively. The vast
majority (94%) of sites (rr: 57100%) reported conducting at
least one form of outreach and tracking for ART-treated
adults with missed clinic visits; and 98% (rr: 93100%)
provided one or more ART adherence support services on a
routine basis. According to survey responses, nutritional
counselling (70%; rr: 6386%) and micronutrient supplemen-
tation (54%; rr: 4060%) were not as universally available
although relatively uniform across regions. PMTCT services
were reported to be available onsite at 77% and offsite at
11% of all adult HIV clinics.
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Caribbean, Central and South America (n=7)
Argentina (1)
Brazil (1)
Chile (1)
Haiti (1)
Honduras (1)
Mexico (1)
Peru (1)
Central Africa (n=12)
Burundi (1)
Cameroon (3)
Democratic Republic of 
Congo (6)
Rwanda (2)
East Africa (n=51)
Kenya (42)
Tanzania (3)
Uganda (6)
West Africa (n=15)
Benin (2)
Burkina Faso (1)
Cote d’Ivoire (6)
Mali (2)
Nigeria (2)
Senegal (1)
Republic of Gambia (1)
Asia-Pacific (n=20)
Australia (4)
Cambodia (1)
China (2)
India (1)
Indonesia (2)
Japan (1)
Malaysia (2)
Philippines (1)
Republic of Korea (1)
Singapore (1)
Taiwan (1)
Thailand (3)
Southern Africa (n=16)
Botswana (1)
Malawi (1)
Mozambique (1)
South Africa (10)
Zambia (1)
Zimbabwe (2)
North America
(NA-ACCORD) (n=7)
USA (6)
Canada (1)
Figure 1. Geographical distribution of the HIV treatment programmes from the IeDEA network that participated in the site assessment.
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HIV laboratory capacity
All but four clinics reported having CD4 cell count testing
available either onsite (59%; rr: 3786%) or offsite (38%;
rr: 1459%), with a median turnaround time of three days
(interquartile range: 110) (Table 2). Additionally, 23% (rr: 0
67%) reported experiencing a CD4 cell count reagent stock-
out in the 12 months preceding the survey. Overall, 82% of
sites (rr: 58100%) reported having access to HIV-1 plasma
RNA (viral load) testing, although onsite viral load testing was
uncommon (30%, rr: 071%).
ART provision
Across all seven IeDEA regions, 34% (rr: 050%) of clinics
reported having a waiting list for ART patients, as shown
in Table 3. Only 82 of the 128 clinics (64%; rr: 33100%)
reported no ARV medication stock-outs in the 12 months
preceding the survey.
Screening, diagnosis and management of TB and malaria
TB symptom screening was conducted among the HIV clinic
populations at 77% of sites, with variability across regions
Table 1. Adult HIV care and treatment facility characteristics by region
North
America
Latin
America
Asia-
Pacific
Central
Africa
East
Africa
Southern
Africa
West
Africa
All
Regions
N7 N7 N20 N12 N51 N16 N15 N128
Patient population, n (%)
Urban 6 (86%) 7 (100%) 17 (85%) 8 (67%) 17 (33%) 14 (88%) 9 (60%) 78 (61%)
Rural     14 (27%) 2 (13%)  16 (13%)
Mixed 1 (14%)  3 (15%) 4 (33%) 20 (39%)  6 (40%) 34 (27%)
Patients seen in clinic, n (%)
Adults only 5 (71%) 3 (43%) 13 (65%) 1 (8%) 2 (4%) 1 (6%) 5 (33%) 30 (23%)
Adults and children 2 (29%) 4 (57%) 7 (35%) 11 (92%) 49 (96%) 15 (94%) 10 (67%) 98 (77%)
Level of facility, n (%)a,b
Missingb     2 (4%)   2 (2%)
Primary 2 (29%) 1 (14%) 1 (5%) 7 (58%) 24 (49%) 9 (56%) 4 (27%) 48 (38%)
Secondary   1 (5%) 1 (8%) 18 (37%) 4 (25%) 2 (13%) 26 (21%)
Tertiary 5 (71%) 6 (86%) 18 (90%) 4 (33%) 7 (14%) 3 (19%) 9 (60%) 52 (41%)
Type of facility, n (%)b
Missing    1 (8%) 2 (4%)   3 (2%)
Public 4 (57%) 6 (86%) 18 (90%) 5 (45%) 44 (90%) 10 (63%) 12 (80%) 99 (79%)
Private 3 (43%) 1 (14%) 2 (10%) 6 (55%) 5 (10%) 6 (38%) 3 (20%) 26 (21%)
Year ART services began, n (%)
B2000 7 (100%) 3 (43%) 17 (85%)  1 (2%) 2 (13%) 4 (27%) 34 (27%)
20002004  3 (43%) 2 (10%) 4 (33%) 17 (33%) 11 (69%) 10 (67%) 47 (37%)
2005 and later  1 (14%) 1 (5%) 7 (58%) 28 (55%) 2 (13%)  39 (30%)
Number of sites with provider category on staff, n (%)
Physicians 7 (100%) 7 (100%) 20 (100%) 12 (100%) 31 (61%) 15 (94%) 14 (93%) 106 (83%)
Paediatricians 2 (29%) 4 (57%) 9 (45%) 2 (17%) 14 (27%) 9 (56%) 7 (47%) 47 (37%)
Mid-level providersc 6 (86%) 2 (29%) 8 (40%) 4 (33%) 44 (86%) 5 (31%) 3 (20%) 72 (56%)
Nurses/midwives 7 (100%) 7 (100%) 19 (95%) 8 (67%) 45 (88%) 16 (100%) 12 (80%) 114 (89%)
Nursing assistantsd 6 (86%) 4 (57%) 11 (55%) 6 (50%) 10 (20%) 5 (33%) 42 (33%)
Lay health workers, adherence
counsellors or outreach workers
7 (100%) 6 (86%) 14 (70%) 10 (83%) 44 (86%) 14 (88%) 13 (87%) 108 (84%)
Pharmacists 7 (100%) 5 (71%) 18 (90%) 5 (42%) 12 (24%) 13 (81%) 12 (80%) 72 (56%)
Pharmacy assistants 5 (71%) 5 (71%) 8 (40%) 7 (58%) 38 (75%) 13 (81%) 12 (80%) 88 (69%)
Nutritionistsd 6 (86%) 3 (43%) 10 (50%) 5 (42%) 28 (55%) 5 (33%) 57 (45%)
Data capturers 7 (100%) 6 (86%) 17 (85%) 11 (92%) 24 (47%) 13 (81%) 14 (93%) 92 (72%)
aPrimary facilities are health centres or clinics. Secondary facilities are district or provincial hospitals. Tertiary facilities are teaching or national
reference hospitals. Some sites reported more than one facility type. When possible, their responses were disambiguated based on their
reported mean number of HIV patients seen daily; bpercentages are computed using the number of facilities with a non-missing value; cmid-level
providers include clinical officers, nurse practitioners and physician assistants; dSouthern Africa did not query its sites about these provider
categories.
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Table 2. Adult HIV programme characteristics and laboratory capacity reported by region
Total n (%)
North
America
N7
Latin
America
N7
Asia-
Pacific
N20
Central
Africa
N12
East
Africa
N51
West
Africa
N15
Total
N112a
Availability of prevention services
HIV counselling and testing 6 (86%) 6 (86%) 20 (100%) 12 (100%) 51 (100%) 14 (93%) 109 (97%)
Counselling regarding disclosure to partners 7 (100%) 6 (86%) 18 (90%) 10 (83%) 51 (100%) 13 (87%) 105 (94%)
Education on sexual behaviour changes/safer sex 7 (100%) 5 (71%) 19 (95%) 11 (92%) 48 (94%) 8 (53%) 98 (88%)
Provision of condoms 7 (100%) 6 (86%) 14 (70%) 9 (75%) 47 (92%) 7 (47%) 90 (80%)
Family planning for PMTCT 6 (86%) 5 (71%) 15 (75%) 5 (42%) 47 (92%) 7 (47%) 85 (76%)
Referral for onsite screening for sexually
transmitted infections
7 (100%) 5 (71%) 17 (85%) 6 (50%) 45 (88%) 8 (53%) 88 (79%)
Education on high-risk substance use behaviours
and harm reduction practices
7 (100%) 3 (43%) 13 (65%) 5 (42%) 32 (63%) 5 (33%) 65 (58%)
Screening for drug and alcohol abuse and referral
to treatment
7 (100%) 1 (14%) 12 (60%) 3 (25%) 17 (33%) 3 (20%) 43 (38%)
Post-exposure prophylaxis (PEP) 6 (86%) 4 (57%) 19 (95%) 10 (83%) 42 (82%) 12 (80%) 93 (83%)
Male circumcision for adults 2 (29%)  3 (15%) 2 (17%) 33 (65%) 3 (20%) 43 (38%)
Co-trimoxazole prophylaxis 7 (100%) 7 (100%) 20 (100%) 11 (92%) 50 (98%) 14 (93%) 109 (97%)
Other  1 (14%)  1 (8%) 8 (16%) 1 (7%) 11 (10%)
None of the above     2 (4%) 1 (7%) 3 (3%)
Availability of support services
Support groups 6 (86%) 7 (100%) 16 (80%) 11 (92%) 46 (90%) 13 (87%) 99 (88%)
Peer educator programme 5 (71%) 5 (71%) 13 (65%) 6 (50%) 38 (75%) 8 (53%) 75 (67%)
Outreach programme
(pre-ART and/or ART)
5 (71%) 3 (43%) 10 (50%) 10 (83%) 44 (86%) 13 (87%) 85 (76%)
Other 1 (14%) 1 (14%)  1 (8%) 2 (4%) 1 (7%) 6 (5%)
None of the above   2 (10%)  1 (2%) 2 (13%) 5 (5%)
Outreach methods
Phone call 6 (86%) 2 (29%) 18 (90%) 9 (75%) 36 (71%) 12 (80%) 83 (74%)
Letter sent 5 (71%)  6 (30%)    11 (10%)
Home visit  2 (29%) 6 (30%) 11 (92%) 48 (94%) 12 (80%) 79 (71%)
Consult pharmacy  3 (43%) 6 (30%) 3 (25%) 15 (29%) 3 (20%) 30 (27%)
Check hospital records 1 (14%)  6 (30%) 4 (33%) 24 (47%) 2 (13%) 37 (33%)
None of the above  3 (43%) 1 (5%) 1 (8%) 1 (2%) 1 (7%) 7 (6%)
Availability of ART adherence support services
Counselling (one-on-one) 7 (100%) 7 (100%) 19 (95%) 11 (92%) 50 (98%) 14 (93%) 108 (96%)
Counselling (group) 3 (43%) 3 (43%) 4 (20%) 9 (75%) 45 (88%) 11 (73%) 75 (67%)
Educational materialsb 6 (86%) 3 (43%) 15 (75%) 7 (58%) 29 (57%) 4 (27%) 64 (57%)
Reminder toolsc 7 (100%) 4 (57%) 15 (75%) 10 (83%) 45 (88%) 7 (47%) 88 (79%)
Routine review of medication pick-up 5 (71%) 5 (71%) 9 (45%) 5 (42%) 38 (75%) 9 (60%) 71 (63%)
None of the above     1 (2%) 1 (7%) 2 (2%)
Availability of nutritional services for adult patients
Nutritional counselling 6 (86%) 6 (86%) 15 (75%) 9 (75%) 32 (63%) 10 (67%) 78 (70%)
Any nutrition support 6 (86%) 7 (100%) 15 (75%) 11 (92%) 51 (100%) 12 (80%) 102 (91%)
Micronutrient supplementation 4 (57%) 4 (57%) 8 (40%) 6 (50%) 29 (57%) 9 (60%) 60 (54%)
Nutritional ‘‘treatment’’ for severely malnourished
adults
4 (57%) 1 (14%) 9 (45%) 4 (33%) 37 (73%) 4 (27%) 59 (53%)
Food rations  2 (29%)  5 (42%) 28 (55%) 8 (53%) 43 (38%)
None   4 (20%)   2 (13%) 6 (5%)
Missing 1 (14%)     1 (7%) 2 (2%)
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ranging from 55% in Asia-Pacific to 100% in Southern Africa.
However, only 41% of sites (rr: 1059%) reported using a
formal TB screening questionnaire. TB skin testing was
available at only 27% of sites (ranging from 4% in East Africa
to 100% in North America). Isoniazid preventative therapy
(IPT) was available for all patients living with HIV at only 25%
(rr: 043%) of clinics and was not available at all in 36% (rr:
080%) of clinics.
TB treatment was located within the HIV care and
treatment facility in 48% of sites (ranging from 14% in North
America to 88% in Southern Africa) and in an onsite TB clinic
in an additional 30% (rr: 071%) (Table 3). The majority of
participating clinics (63%; rr: 4180%) instituted directly
observed TB therapy (TB-DOTS) for TB treatment in adult
patients. Absence of TB-DOTS was most common in clinics
responding from North America (43%) and Asia-Pacific (50%).
The provision of bed nets by sites to patients for malaria
prevention was uncommon in all regions (36%) except in East
Africa (77% of sites). Sites that reported managing malaria
diagnosed most malaria cases using thick smears (77%; rr:
67100%).
Comprehensiveness of HIV care
Table 4 summarizes the distribution of seven essential HIV
care services by IeDEA region. Comprehensiveness measures
were calculated for the 93 sites (73%) for which complete
survey data were available. Sites with missing data, which
included all sites in Southern Africa, were excluded from the
analysis, although sensitivity analyses were performed that
included sites with partial data. Twenty of the 93 sites (22%)
offered only 35 essential services (low); 30 sites (32%)
offered 6 essential services (medium); and 43 sites (46%)
were fully comprehensive, offering all 7 essential services
(high). CD4 cell count testing was available either onsite or
offsite at all sites (100%), whereas universal TB screening and
community outreach/tracking of adults on ART services were
offered least often at 80 and 72%, respectively. Nutritional
support (82%), ART adherence support (88%), PMTCT services
(94%) and prevention and clinical management services
(97%) were available more frequently.
The characteristics of low, medium and highly compre-
hensive facilities are summarized in Table 5. Among the
43 fully comprehensive sites, 74% began ART provision in
Table 2 (Continued )
Total n (%)
North
America
N7
Latin
America
N7
Asia-
Pacific
N20
Central
Africa
N12
East
Africa
N51
West
Africa
N15
Total
N112a
Availability of PMTCT services
Onsite 5 (71%) 6 (86%) 13 (65%) 7 (58%) 46 (90%) 9 (60%) 86 (77%)
Offsite   3 (15%) 3 (25%) 4 (8%) 2 (13%) 12 (11%)
None  1 (14%) 4 (20%) 2 (17%)  2 (13%) 9 (8%)
Missing 2 (29%)    1 (2%) 2 (13%) 5 (4%)
Laboratory capacity
CD4 cell count testing
Onsite 5 (71%) 6 (86%) 17 (85%) 9 (75%) 19 (37%) 10 (67%) 66 (59%)
Offsite 2 (29%) 1 (14%) 3 (15%) 3 (25%) 30 (59%) 3 (20%) 42 (38%)
Not available     1 (2%)  1 (1%)
Missing     1 (2%) 2 (13%) 3 (3%)
CD4 turnaround timed
Turnaround days (median, IQR) 1 (12.5) 7 (210) 2 (15.5) 2 (1.754.25) 7 (114) 8 (3.511) 3 (110)
Missing (n,%)  2 (29%) 1 (5%) 1 (8%) 9 (18%) 4 (27%) 17 (15%)
CD4 reagent stock-outs in last 12 monthsd
Yes  1 (14%) 1 (5%) 8 (67%) 14 (27%) 2 (13%) 26 (23%)
No 6 (86%) 5 (71%) 18 (90%) 1 (8%) 29 (57%) 10 (67%) 69 (62%)
Missing 1 (14%) 1 (14%) 1 (5%) 3 (25%) 7 (14%) 3 (20%) 16 (14%)
HIV RNA PCR testing
Onsite 5 (71%) 4 (57%) 14 (70%)  6 (12%) 5 (33%) 34 (30%)
Offsite 2 (29%) 2 (29%) 3 (15%) 7 (58%) 37 (73%) 7 (47%) 58 (52%)
Not available    5 (42%) 5 (10%) 1 (7%) 11 (10%)
Missing  1 (14%) 3 (15%)  3 (6%) 2 (13%) 9 (8%)
aThe 16 sites from Southern Africa are excluded as their survey did not contain these questions; beducational materials include written and
pictorial patient education material and educational videotapes; creminder tools include appointment slips, calendars, checklists or other
reminders, alarm clocks, wrist watches and beepers; dsites reporting no CD4+ measurement capabilities are excluded from the N in these
calculations.
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Table 3. Antiretroviral provision and management of tuberculosis and malaria
Total n (%)
North
America
Latin
America
Asia-
Pacific
Central
Africa
East
Africa
Southern
Africa
West
Africa
All
regions
N7 N7 N20 N12 N51 N16 N15 N128
ART provision
Current waiting list for ART patients (N,%)
Yes   2 (10%) 6 (50%) 23 (45%) 5 (31%) 7 (47%) 43 (34%)
No  7 (100%) 18 (90%) 6 (50%) 28 (55%) 11 (69%) 7 (47%) 77 (60%)
Missing 7 (100%)      1 (7%) 8 (6%)
Duration of ART medication stock-outs in last 12 months
1 day only   1 (5%) 1 (8%) 1 (2%)   3 (2%)
27 days   1 (5%) 2 (17%) 1 (2%)  2 (13%) 6 (5%)
821 days  1 (14%)   4 (8%)  2 (13%) 7 (5%)
21 days  1 (14%)  3 (25%) 2 (4%)  2 (13%) 8 (6%)
Duration unknown  1 (14%)  1 (8%) 1 (2%)  3 (20%) 12 (9%)
No stock-outs  4 (57%) 17 (85%) 5 (42%) 41 (80%) 6 (38%) 5 (33%) 82 (64%)
Missing 7 (100%)  1 (5%)  1 (2%) 10 (63%) 1 (7%) 10 (8%)
Tuberculosis
Location of TB treatment services
Within onsite HIV care and treatment facility 1 (14%) 2 (29%) 11 (55%) 4 (33%) 18 (35%) 14 (88%) 11 (73%) 61 (48%)
Onsite TB clinic 1 (14%) 5 (71%) 6 (30%) 2 (17%) 24 (47%)  1 (7%) 39 (30%)
Offsite TB clinic 5 (71%)  3 (15%) 5 (42%) 5 (10%) 2 (13%) 2 (13%) 22 (17%)
Missing    1 (8%) 4 (8%)  1 (7%) 6 (5%)
TB screeninga
Ask about symptoms as standard part
of patient history
4 (57%) 6 (86%) 11 (55%) 10 (83%) 39 (76%) 16 (100%) 12 (80%) 98 (77%)
Formal questionnaire 1 (14%) 1 (14%) 2 (10%) 5 (42%) 30 (59%) 7 (44%) 6 (40%) 52 (41%)
Tuberculin skin test 7 (100%) 6 (86%) 6 (30%) 3 (25%) 2 (4%) 7 (44%) 3 (20%) 34 (27%)
DOTS for adult TB patients
First 2 months  1 (14%) 1 (5%) 4 (33%) 19 (37%) 6 (38%) 6 (40%) 37 (29%)
Entire period 4 (57%) 4 (57%) 9 (45%) 1 (8%) 13 (25%) 6 (38%) 6 (40%) 43 (34%)
No 3 (43%) 2 (29%) 10 (50%) 3 (25%) 12 (24%) 4 (25%) 2 (13%) 36 (28%)
Missing    4 (33%) 7 (14%)  1 (7%) 12 (9%)
Availability of isoniazid prophylaxis
For all patients  3 (43%) 4 (20%) 1 (8%) 20 (39%) 2 (13%) 2 (13%) 32 (25%)
For some patients  4 (57%) 11 (55%) 3 (25%) 5 (10%) 13 (81%) 1 (7%) 37 (29%)
Not available   5 (25%) 7 (58%) 21 (41%) 1 (6%) 12 (80%) 46 (36%)
Missing 7 (100%)   1 (8%) 5 (10%)   13 (10%)
Malaria
Malaria diagnostic methods
Presumptive diagnosis  1 (14%) 2 (10%) 5 (42%) 35 (69%) 3 (19%) 9 (60%) 55 (43%)
Thick smear  5 (71%) 16 (80%) 12 (100%) 45 (88%) 11 (69%) 10 (67%) 99 (77%)
Rapid test  1 (14%) 6 (30%) 1 (8%) 13 (25%) 9 (56%) 6 (40%) 36 (28%)
Other   2 (10%)    1 (7%) 3 (2%)
Not applicable  2 (29%) 2 (10%)   3 (19%)  7 (5%)
Missing 7 (100%)     1 (6%) 1 (7%) 9 (7%)
Distribution of free bed netsb
All patients   1 (5%)  7 (14%)  2 (13%) 10 (8%)
Targeted distribution   1 (5%) 2 (17%) 32 (63%)  1 (7%) 36 (28%)
Not distributed/not applicable  7 (100%) 18 (90%) 10 (83%) 11 (22%)  11 (73%) 57 (45%)
Missing 7 (100%)    1 (2%) 16 (100%) 1 (7%) 25 (20%)
aTB screening includes screening done on all patients only; bone site reported that it did not distribute free bed nets, while also
saying it distributed free bed nets to pregnant women and paediatric patients under age 5. This site was only included under targeted
distribution.
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20002009 with the vast majority (90%) providing services to
both adults and children. Among 21 sites located in high-
ranked or very high-ranked countries according to the 2010
HDI, 48% had low numbers of essential services where 43%
performed patient outreach, 62% offered TB screening and
76% offered nutritional support programmes. Sites located in
low-HDI countries receiving PEPFAR funding tended to offer
more comprehensive services, with 94% of sites having 67
essential services.
Discussion
The survey of site capacity in this large global HIV care
consortium revealed substantial regional variability in HIV care
and treatment programmes and the comprehensiveness
of HIV-associated services. Unexpectedly, IeDEA-participating
HIV care and treatment sites in low-HDI settings were more
likely to offer the full complement of essential services, com-
pared to sites with medium or high HDI rankings. This dif-
ference appeared to be driven in part by low-HDI countries
whose national programmes received PEPFAR support (72% of
clinics reported having all seven essential services) compared
with those low-HDI countries whose national programmes did
not receive PEPFAR support (9% reported having all seven
essential services). As international donor support for HIV care
and treatment is waning, it will be important to track the
continued availability of these comprehensive services over
time, especially in the midst of and following full transitioning
of care services to national authorities.
The lack of availability of all seven essential services at
participating sites in middle- and high-HDI settings was surprising.
The low prevalence of TB and malnutrition in such settings
may lead to less emphasis on WHO-recommended services
such as TB screening and nutritional support. This may also
reflect the structure of how HIV care is provided in most high-
HDI countries, where general patient care is offered through
distributed, fee-for-service health delivery systems, compared
to lower income countries where programmes are structured
for a public health approach. Indeed, patients in high-HDI
countries may be receiving equal or more comprehensive
care, but at health facilities outside the HIV clinic.
Table 4. Reported distribution of HIV services by IeDEA regiona
Service by region
Offered
Not
offered Missing
% Offered (of
non-missing)
North America (n7)
ART adherence 6 1 0 86
Nutritional support 7 0 0 100
PMTCT 5 1 1 83
CD4 testing 7 0 0 100
TB screening 4 3 0 57
Prevention 6 1 0 86
Outreach 5 2 0 71
Latin America (n7)
ART adherence 7 0 0 100
Nutritional support 4 3 0 57
PMTCT 6 1 0 86
CD4 testing 7 0 0 100
TB screening 6 1 0 86
Prevention 5 2 0 71
Outreach 3 4 0 43
Asia-Pacific (n20)
ART adherence 18 2 0 90
Nutritional support 15 5 0 75
PMTCT 17 3 0 85
CD4 testing 20 0 0 100
TB screening 11 9 0 55
Prevention 20 0 0 100
Outreach 9 11 0 45
Central Africa (n12)
ART adherence 9 3 0 75
Nutritional support 8 1 3 89
PMTCT 10 2 0 83
CD4 testing 12 0 0 100
TB screening 10 1 1 91
Prevention 12 0 0 100
Outreach 6 6 0 50
East Africa (n51)
ART adherence 41 8 2 84
Nutritional support 46 5 0 90
PMTCT 50 1 0 98
CD4 testing 49 1 1 98
TB screening 39 6 6 87
Prevention 51 0 0 100
Outreach 44 6 1 88
Vest Africa (n17)
ART adherence 11 2 2 85
Nutritional support 10 4 1 71
PMTCT 12 1 2 92
CD4 testing 15 0 2 100
TB screening 12 3 0 80
Prevention 15 0 1 100
Outreach 9 4 2 69
Table 4 (Continued )
Service by region
Offered
Not
offered Missing
% Offered (of
non-missing)
All regions (n112)
ART adherence 92 16 4 85
Nutritional support 90 18 4 83
PMTCT 100 9 3 92
CD4 testing 108 1 3 99
TB screening 82 23 7 78
Prevention 108 3 1 97
Outreach 76 33 3 70
aIeDEA Southern Africa is not represented in the essential services
summary as data were not available for this region.
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Our study identified opportunities to improve the compre-
hensiveness of HIV care within the global IeDEA consortium.
IeDEA clinics should aim to provide evidence-based services
that support retention in care, including ART adherence
support services, active patient outreach and peer support
groups [20,34]. Almost all clinics in IeDEA reported providing
one-on-one counselling for ART adherence support, but did
not offer alternatives for adherence support or coordinate
Table 5. Facility characteristics by level of clinic comprehensivenessa
Comprehensiveness (number of services)
Low (35) (% of row) Medium (6) (% of row) High (7) (% of row) All tiersb (% of all sites)
N20 N30 N43 N93
Region, n (%)
Asia-Pacific 9 (45%) 7 (35%) 4 (20%) 20 (22%)
CCASAnet 3 (43%) 2 (29%) 2 (29%) 7 (8%)
Central Africa 1 (12%) 4 (50%) 3 (38%) 8 (9%)
East Africa 2 (5%) 11 (26%) 29 (69%) 42 (45%)
NA-ACCORD 2 (33%) 3 (50%) 1 (17%) 6 (6%)
West Africa 3 (30%) 3 (30%) 4 (40%) 10 (11%)
Patient population, n (%)
Urban 16 (29%) 16 (29%) 23 (42%) 55 (59%)
Rural  3 (33%) 6 (67%) 9 (10%)
Mixed 4 (14%) 11 (38%) 14 (48%) 29 (31%)
Year of ART provision, n (%)
Missing 1 (5%)  3 (7%) 4 (4%)
19851989 3 (27%) 5 (45%) 3 (27%) 11 (12%)
19901994 3 (60%) 2 (40%)  5 (6%)
19951999 5 (36%) 4 (29%) 5 (36%) 14 (16%)
20002004 6 (19%) 10 (31%) 16 (50%) 32 (36%)
20052009 2 (7%) 9 (33%) 16 (59%) 27 (30%)
Type of facility, n (%)
Missing 1 (5%)  1 (2%) 2 (2%)
Private clinic 3 (25%) 5 (42%) 4 (33%) 12 (13%)
Public or government 16 (20%) 25 (32%) 38 (48%) 79 (87%)
Level of facility, n (%)
Missing 1 (5%)  1 (2%) 2 (2%)
Primary 6 (16%) 11 (29%) 21 (55%) 38 (42%)
Secondary  3 (19%) 13 (81%) 16 (18%)
Tertiary 13 (35%) 16 (43%) 8 (22%) 37 (41%)
Patients seen in clinic, n (%)
Adult only 14 (52%) 9 (33%) 4 (15%) 27 (29%)
Adults and children 6 (9%) 21 (32%) 39 (59%) 66 (71%)
PEPFAR country (2008), n (%)
PEPFAR 3 (6%) 11 (22%) 36 (72%) 50 (54%)
No PEPFAR 17 (40%) 19 (44%) 7 (16%) 43 (46%)
HDI income category (2010), n (%)
UN HDI-low 6 (10%) 18 (30%) 37 (61%) 61 (66%)
UN HDI-middle 4 (36%) 4 (36%) 3 (27%) 11 (12%)
UN HDI-high/very high 10 (48%) 8 (38%) 3 (14%) 21 (23%)
PEPFAR (2008) and HDI (2010), n (%)
No PEPFAR: UN HDI-high/very high 10 (48%) 8 (38%) 3 (14%) 21 (23%)
No PEPFAR: UN HDI-low 3 (27%) 7 (64%) 1 (9%) 11 (12%)
No PEPFAR: UN HDI-middle 4 (36%) 4 (36%) 3 (27%) 11 (12%)
PEPFAR: UN HDI low 3 (6%) 11 (22%) 36 (72%) 50 (54%)
aIeDEA Southern Africa is not represented in the comprehensiveness analysis as data were not available for this region; bPercentages are
computed using the number of facilities with a non-missing value.
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outreach or peer group programmes. Sites can strengthen
their response to the TB-HIV epidemic by using a formal
questionnaire for TB symptom screening, developing TB
culture capacity, providing isoniazid preventive therapy and
requiring TB-DOTS for TB management. As HIV care and
treatment programmes evolve, these service gaps need to be
filled through advance planning for both new and existing
HIV care sites.
This work brings together and reinforces the conclusions
of other studies that addressed gaps in the availability of
nutritional support services [35] and TB diagnostic capacity
[36] in sub-Saharan Africa, gaps in HIV prevention services
[37] and paediatric HIV services globally [38], and the diverse
characteristics of PEPFAR-sponsored HIV programmes [39].
The breadth of this survey, with 128 adult HIV care facilities
in 41 countries worldwide, including facilities at all levels of
the health care system and in both urban and rural settings,
offers a rare perspective on the variability of global HIV service
availability. Sites in IeDEA are part of a research network and
not representative of all HIV care and treatment sites in their
respective regions, or the full range of HIV clinics worldwide.
Nevertheless, the diversity in survey participants allowed us
to examine a wide array of programme-level characteristics.
The 96% response rate indicated that electronic surveys
were effective in recruiting participating sites. Nevertheless,
our study was limited as we relied on self-reported assess-
ments of clinic services from HIV clinical providers at each
site. The responses of health facility staff and survey resp-
onses were not independently verified by the research team,
so we cannot rule out the possibility of facility staff over- or
underreporting the availability of specific aspects of HIV
services. Where possible, however, we checked the internal
consistency of the survey data and resolved any discrepan-
cies by consulting with regional data managers.
Finally, the HIV clinic survey only collected the self-
reported availability of HIV prevention, care and treatment
services and did not assess patient access to, routine use of
and quality of these services. This limited our ability to assess
actual care capacity at IeDEA sites and hence our clinic
comprehensiveness metric. True comprehensive HIV care and
its associated positive patient outcomes depend on acces-
sible, high-quality clinic services. Furthermore, in developing
our metric, we reviewed the HIV prevention, care and
treatment services recommended by WHO and the published
literature on comprehensive care. The final components of
our comprehensiveness metric, however, were limited to
data that had been collected in the IeDEA site survey. We
intend to incorporate the most recent WHO comprehen-
sive HIV services definition in a future iteration of the site
capacity questionnaire.
Conclusions
Data from this global site survey suggest that HIV prevention,
care and treatment clinics worldwide vary greatly in capacity
and that clinics more recently established in low-resource
settings may offer a more comprehensive array of services
onsite. Respondents reported frequently that contact tracing
of patients, patient outreach, nutritional counselling, onsite
viral load testing, universal TB screening and the provision of
isoniazid preventive therapy were unavailable at their HIV
clinics. Factors such as year of initiation of services, country
HDI category and national HIV programme support from
external donors such as PEPFAR appeared to contribute to
the comprehensiveness of care at sites in the IeDEA network.
This study provides a baseline from which to assess future
changes in HIV programme structure in the context of
transitions of HIV management to national authorities and
decreased global funding.
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